{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:34:20Z","timestamp":1787502860674,"version":"build-2736575974"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["19\/2021"],"award-info":[{"award-number":["19\/2021"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Psoriatic arthritis (PA) is a chronic inflammatory systemic arthritis that can result in loss of functional capacity and joint deformation. This systematic review assessed the effectiveness and safety of biological and target synthetic drugs for treating PA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched for randomized clinical trials (RCTs) that evaluated the use of Adalimumab, Etanercept, Infliximab, Golimumab, Secukinumab, Certolizumab Pegol and Tofacitinib in the main general databases and clinical trial registers databases. The primary outcomes were ACR 50, PsARC, and serious adverse events. Two independent reviewers performed study selection and data extraction. Network meta-analyses were conducted using a random effects model and frequentist approach. The CINeMA software was used to assess the certainty of evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 33 RCTs (n\u2009=\u200911,034). The results from the network meta-analysis for the ACR 50 at 6-months follow-up showed that all drugs were superior to placebo, with Secukinumab (high certainty of evidence), Infliximab (very low certainty of evidence) and Adalimumab (high certainty of evidence) ranking the highest. Regarding the PsARC (at 6-months follow-up), all drugs, except for Golimumab (very low certainty of evidence), were superior to placebo, with Etanercept (low certainty of evidence), Infliximab (low certainty of evidence) and Certolizumab Pegol (low certainty of evidence) being the most effective drugs. There were no significant differences in the risk of serious adverse events between the drugs and placebo. Golimumab (very low certainty of evidence), Secukinumab (low certainty of evidence), and Adalimumab (very low certainty of evidence) ranked the highest for safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In conclusion, based on the balance between efficacy and safety, Secukinumab and Adalimumab may be the preferred options among the evaluated drugs for treating patients with PsA. However, caution is necessary when interpreting the safety findings, as they are supported by evidence of low to very low certainty. Consequently, the balance between benefits and potential risks may change as new safety evaluation studies become available.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Protocol registration<\/jats:title>\n                    <jats:p>PROSPERO: CRD42022315577<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s42358-024-00361-3","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T12:01:52Z","timestamp":1711022512000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effectiveness and safety of biological and target synthetic drugs treatment for psoriatic arthritis: a systematic review with network meta-analysis"],"prefix":"10.1186","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7669-5732","authenticated-orcid":false,"given":"Thais","family":"Montezuma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia Fernandes","family":"Probst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matheus Oliveira","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,21]]},"reference":[{"issue":"10","key":"361_CR1","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017 Mar 9;376(10):957\u201370.","journal-title":"N Engl J Med"},{"issue":"4","key":"361_CR2","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","volume":"41","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am. 2015 Nov;41(4):545\u201368.","journal-title":"Rheum Dis Clin North Am"},{"issue":"4","key":"361_CR3","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1002\/art.39494","volume":"68","author":"L Eder","year":"2016","unstructured":"Eder L, Haddad A, Rosen CF, Lee KA, Chandran V, Cook R, et al. The incidence and risk factors for psoriatic arthritis in patients with psoriasis: a prospective cohort study. Arthritis Rheumatol. 2016 Apr;68(4):915\u201323.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"361_CR4","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/MAJ.0b013e31820f8caf","volume":"341","author":"PD Sampaio-Barros","year":"2011","unstructured":"Sampaio-Barros PD. Epidemiology of spondyloarthritis in Brazil. Am J Med Sci. 2011 Apr;341(4):287\u201388.","journal-title":"Am J Med Sci"},{"issue":"6","key":"361_CR5","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1093\/rheumatology\/keg217","volume":"42","author":"NJ McHugh","year":"2003","unstructured":"McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford). 2003 Jun;42(6):778\u201383.","journal-title":"Rheumatology (Oxford)"},{"key":"361_CR6","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. Protocolos Clinicos e Diretrizes Terap\u00eauticas: Artrite Psor\u00edaca [Internet]. 2021. Available from: https:\/\/www.gov.br\/conitec\/pt-br\/midias\/consultas\/relatorios\/2021\/20210217_relatorio_pcdt_artrite_psoriaca_cp05.pdf"},{"issue":"6","key":"361_CR7","doi-asserted-by":"publisher","first-page":"700.1","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020 Jun;79(6):700.1\u2013712.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"361_CR8","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.2217\/cer-2018-0075","volume":"7","author":"IB McInnes","year":"2018","unstructured":"McInnes IB, Nash P, Ritchlin C, Choy EH, Kanters S, Thom H, et al. Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics\/apremilast: a network meta-analysis. J Comp Eff Res. 2018 Nov;7(11):1107\u201323.","journal-title":"J Comp Eff Res"},{"issue":"1","key":"361_CR9","doi-asserted-by":"publisher","first-page":"e002074","DOI":"10.1136\/rmdopen-2021-002074","volume":"8","author":"IB McInnes","year":"2022","unstructured":"McInnes IB, Sawyer LM, Markus K, LeReun C, Sabry-Grant C, Helliwell PS. Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes. RMD Open. 2022 Mar;8(1):e002074.","journal-title":"RMD Open"},{"issue":"3","key":"361_CR10","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.semarthrit.2019.06.001","volume":"49","author":"C Lu","year":"2019","unstructured":"Lu C, Wallace BI, Waljee AK, Fu W, Zhang Q, Liu Y. Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: a systematic review and network meta-analysis. Semin Arthritis Rheum. 2019 Dec;49(3):381\u201388.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"361_CR11","doi-asserted-by":"publisher","first-page":"e001117","DOI":"10.1136\/rmdopen-2019-001117","volume":"6","author":"A Ruyssen-Witrand","year":"2020","unstructured":"Ruyssen-Witrand A, Perry R, Watkins C, Braileanu G, Kumar G, Kiri S, et al. Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis. RMD Open. 2020 Feb;6(1):e001117.","journal-title":"RMD Open"},{"key":"361_CR12","unstructured":"Cochrane handbook for systematic reviews of interventions [Internet]. [cited 2022 Aug 12]. Available from: https:\/\/training.cochrane.org\/handbook"},{"key":"361_CR13","unstructured":"da Sa\u00fade M. Diretrizes Metodol\u00f3gicas: Elabora\u00e7\u00e3o de Revis\u00e3o Sistem\u00e1tica e Meta-an\u00e1lise de ensaios cl\u00ednicos randomizados [Internet]. 1 edi\u00e7\u00e3o. 2021. Available from: https:\/\/rebrats.saude.gov.br\/images\/Documentos\/2021\/20210622_Diretriz_Revisao_Sistematica_2021.pdf"},{"issue":"11","key":"361_CR14","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015 Jun 2;162(11):777\u201384.","journal-title":"Ann Intern Med"},{"issue":"5","key":"361_CR15","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3899\/jrheum.170150","volume":"44","author":"A Ogdie","year":"2017","unstructured":"Ogdie A, de Wit M, Duffin KC, Campbell W, Chau J, Coates LC, et al. Defining outcome measures for psoriatic arthritis: a report from the GRAPPA-OMERACT working group. J Rheumatol. 2017 May;44(5):697\u2013700.","journal-title":"J Rheumatol"},{"key":"361_CR16","unstructured":"Veritas Health Innovation. Covidence systematic review software [Internet]. Melbourne, Australia. Available from: www.covidence.org"},{"key":"361_CR17","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. Bmj. 2019 Aug 28;366:l4898.","journal-title":"Bmj"},{"issue":"1","key":"361_CR18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","volume":"15","author":"G R\u00fccker","year":"2015","unstructured":"R\u00fccker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Method. 2015 Jul 31;15(1):58.","journal-title":"BMC Med Res Method"},{"key":"361_CR19","unstructured":"Metelli S, Chaimani A. NMAstudio: a fully interactive web-application for producing and visualising network meta-analyses. In 2021."},{"issue":"4","key":"361_CR20","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/art.20967","volume":"52","author":"CE Antoni","year":"2005","unstructured":"Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 2005 Apr;52(4):1227\u201336.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"361_CR21","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s10067-009-1340-7","volume":"29","author":"M Atteno","year":"2010","unstructured":"Atteno M, Peluso R, Costa L, Padula S, Iervolino S, Caso F, et al. Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. Clin Rheumatol. 2010 Apr;29(4):399\u2013403.","journal-title":"Clin Rheumatol"},{"key":"361_CR22","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1159\/000343290","volume":"225","author":"M de Groot","year":"2012","unstructured":"de Groot M, Picavet DI, van Kuijk AWR, Tak PP, Bos JD, de Rie MA, et al. A prospective, randomized, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on lesional and nonlesional skin. Dermatology 2012;225:298\u2013303.","journal-title":"Dermatology"},{"issue":"5","key":"361_CR23","first-page":"1040","volume":"34","author":"MC Genovese","year":"2007","unstructured":"Genovese MC, Mease PJ, Thomson GTD, Kivitz AJ, Perdok RJ, Weinberg MA, et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol. 2007 May;34(5):1040\u201350.","journal-title":"J Rheumatol"},{"issue":"3","key":"361_CR24","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s40744-019-0163-5","volume":"6","author":"AJ Kivitz","year":"2019","unstructured":"Kivitz AJ, Nash P, Tahir H, Everding A, Mann H, Kaszuba A, et al. Efficacy and safety of subcutaneous secukinumab 150 mg with or without loading regimen in psoriatic arthritis: results from the FUTURE 4 study. Rheumatol Ther. 2019 Sep;6(3):393\u2013407.","journal-title":"Rheumatol Ther"},{"issue":"2","key":"361_CR25","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1136\/annrheumdis-2012-202646","volume":"73","author":"IB McInnes","year":"2014","unstructured":"McInnes IB, Sieper J, Braun J, Emery P, van der Heijde D, Isaacs JD, et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis. 2014 Feb;73(2):349\u201356.","journal-title":"Ann Rheum Dis"},{"issue":"9999","key":"361_CR26","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","volume":"386","author":"IB McInnes","year":"2015","unstructured":"McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015 Sep;386(9999):1137\u201346.","journal-title":"Lancet"},{"issue":"9227","key":"361_CR27","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","volume":"356","author":"PJ Mease","year":"2000","unstructured":"Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000 Jul 29;356(9227):385\u201390.","journal-title":"Lancet"},{"issue":"1","key":"361_CR28","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13075-018-1551-x","volume":"20","author":"P Nash","year":"2018","unstructured":"Nash P, Mease PJ, McInnes IB, Rahman P, Ritchlin CT, Blanco R, et al. Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). Arthritis Res Ther. 2018 Mar 15;20(1):47.","journal-title":"Arthritis Res Ther"},{"key":"361_CR29","doi-asserted-by":"crossref","unstructured":"Mease P, van der Heijde D, Landew\u00e9 R, Mpofu S, Rahman P, Tahir H, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis 2018 Mar 17;annrheumdis-2017-212687.","DOI":"10.1136\/annrheumdis-2017-212687"},{"issue":"1","key":"361_CR30","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-na\u00efve patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017 Jan;76(1):79\u201387.","journal-title":"Ann Rheum Dis"},{"issue":"16","key":"361_CR31","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","volume":"377","author":"P Mease","year":"2017","unstructured":"Mease P, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila-Zapata F, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017 Oct 19;377(16):1537\u201350.","journal-title":"N Engl J Med"},{"issue":"13","key":"361_CR32","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","volume":"384","author":"IB McInnes","year":"2021","unstructured":"McInnes IB, Anderson JK, Magrey M, Merola JF, Liu Y, Kishimoto M, et al. Trial of upadacitinib and adalimumab for psoriatic arthritis. N Engl J Med. 2021 Apr 1;384(13):1227\u201339.","journal-title":"N Engl J Med"},{"issue":"8","key":"361_CR33","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1136\/ard.2004.032268","volume":"64","author":"C Antoni","year":"2005","unstructured":"Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005 Aug;64(8):1150\u201357.","journal-title":"Ann Rheum Dis"},{"issue":"14","key":"361_CR34","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","volume":"373","author":"PJ Mease","year":"2015","unstructured":"Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015 Oct;373(14):1329\u201339.","journal-title":"N Engl J Med"},{"key":"361_CR35","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1093\/rheumatology\/keab628","volume":"61","author":"MA D\u2019Agostino","year":"2021","unstructured":"D\u2019Agostino MA, Schett G, L\u00f3pez-Rdz A, \u0160enolt L, Fazekas K, Burgos-Vargas R, et al. Response to secukinumab on synovitis using Power Doppler ultrasound in psoriatic arthritis: 12-week results from a phase III study, ULTIMATE. Rheumatology (Oxford) 2021;61:1867\u201376.","journal-title":"Rheumatology (Oxford)"},{"issue":"16","key":"361_CR36","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","volume":"377","author":"D Gladman","year":"2017","unstructured":"Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017 Oct 19;377(16):1525\u201336.","journal-title":"N Engl J Med"},{"issue":"3","key":"361_CR37","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/acr.23111","volume":"69","author":"A Kavanaugh","year":"2017","unstructured":"Kavanaugh A, Mease PJ, Reimold AM, Tahir H, Rech J, Hall S, et al. Secukinumab for long-term treatment of psoriatic arthritis: a two-year followup from a phase III, randomized, double-blind placebo-controlled study. Arthritis Care Res (Hoboken). 2017 Mar;69(3):347\u201355.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"361_CR38","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1136\/annrheumdis-2018-214746","volume":"78","author":"LJJ van Mens","year":"2019","unstructured":"van Mens LJJ, de Jong HM, Fluri I, Nurmohamed MT, van de Sande MGH, Kok M, et al. Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate. Ann Rheum Dis. 2019 May;78(5):610\u201316.","journal-title":"Ann Rheum Dis"},{"key":"361_CR39","doi-asserted-by":"crossref","unstructured":"Mease PJ, Gladman DD, Collier DH, Ritchlin CT, Helliwell PS, Liu L, et al. Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial. Arthritis Rheumatol. 2019. Jul;71(7):1112\u201324.","DOI":"10.1002\/art.40851"},{"issue":"4","key":"361_CR40","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1002\/art.24403","volume":"60","author":"A Kavanaugh","year":"2009","unstructured":"Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009 Apr;60(4):976\u201386.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"361_CR41","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1002\/art.21306","volume":"52","author":"PJ Mease","year":"2005","unstructured":"Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EHS, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005 Oct;52(10):3279\u201389.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"361_CR42","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","volume":"73","author":"PJ Mease","year":"2014","unstructured":"Mease PJ, Fleischmann R, Deodhar AA, Wollenhaupt J, Khraishi M, Kielar D, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2014 Jan;73(1):48\u201355.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"361_CR43","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1136\/ard.2011.152223","volume":"71","author":"A Baranauskaite","year":"2012","unstructured":"Baranauskaite A, Raffayov\u00e1 H, Kungurov NV, Kubanova A, Venalis A, Helmle L, et al. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-na\u00efve patients: the RESPOND study. Ann Rheum Dis. 2012 Apr;71(4):541\u201348.","journal-title":"Ann Rheum Dis"},{"key":"361_CR44","doi-asserted-by":"publisher","first-page":"33.2","DOI":"10.1136\/annrheumdis-2020-eular.2393","volume":"79","author":"L Coates","year":"2020","unstructured":"Coates L, Tillett W, D\u2019agostino M, Rahman P, Behrens F, Conaghan P, et al. Adalimumab introduction versus methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis: results from randomized phase 4 control study. Ann Rheumatic Dis. 2020 Jun 1;79:33.2\u201333.","journal-title":"Ann Rheumatic Dis"},{"key":"361_CR45","unstructured":"EUCTR2019-001996-35-HU. A phase 3, randomized, double-blind, Placebo and Adalimumab-controlled study to evaluate the efficacy and safety of Filgotinib in subjects with active Psoriatic Arthritis who are Na\u00efve to biologic DMARD therapy. https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2019-001996-35-HU [Internet]. 2020 Oct 31 [cited 2022 Dec 1]; Available from: https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-02169233\/full"},{"issue":"10235","key":"361_CR46","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","volume":"395","author":"IB McInnes","year":"2020","unstructured":"McInnes IB, Behrens F, Mease PJ, Kavanaugh A, Ritchlin C, Nash P, et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet. 2020 May;395(10235):1496\u2013505.","journal-title":"Lancet"},{"issue":"7","key":"361_CR47","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1002\/art.20335","volume":"50","author":"PJ Mease","year":"2004","unstructured":"Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004 Jul;50(7):2264\u201372.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"361_CR48","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1136\/annrheumdis-2019-216500","volume":"79","author":"E Vieira-Sousa","year":"2020","unstructured":"Vieira-Sousa E, Alves P, Rodrigues AM, Teixeira F, Tavares-Costa J, Bernardo A, et al. GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-na\u00efve patients with psoriatic arthritis. Ann Rheum Dis. 2020 Apr;79(4):490\u201398.","journal-title":"Ann Rheum Dis"},{"key":"361_CR49","unstructured":"Nguyen T, Churchill M, Levin R, Valenzuela G, Merola J, Ogdie A, et al. A randomized, placebo-controlled study evaluating the safety and efficacy of secukinumab in US biologic-na\u00efve patients with active psoriatic arthritis and psoriatic skin lesions. In: ACR Meeting Abstracts [Internet]. 2019 [cited 2023 Jan 23]. Available from: https:\/\/acrabstracts.org\/abstract\/a-randomized-placebo-controlled-study-evaluating-the-safety-and-efficacy-of-secukinumab-in-us-biologic-na%EFve-patients-with-active-psoriatic-arthritis-and-psoriatic-skin-lesions"},{"issue":"5","key":"361_CR50","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1136\/annrheumdis-2020-218808","volume":"80","author":"X Baraliakos","year":"2021","unstructured":"Baraliakos X, Gossec L, Pournara E, Jeka S, Mera-Varela A, D\u2019Angelo S, et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis. 2021 May;80(5):582\u201390.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"361_CR51","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1136\/ard.2008.091389","volume":"68","author":"AWR van Kuijk","year":"2009","unstructured":"van Kuijk AWR, Gerlag DM, Vos K, Wolbink G, de Groot M, de Rie MA, et al. A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue. Ann Rheum Dis. 2009 Aug;68(8):1303\u201309.","journal-title":"Ann Rheum Dis"},{"key":"361_CR52","unstructured":"EUCTR2016-000972-91-BG. Study of efficacy and safety of secukinumab in Psoriatic Arthritis and axial Spondyloarthritis patients with active enthesitis including one Achilles tendon site (ACHILLES). https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2016-000972-91-BG [Internet]. 2019 Mar 31 [cited 2022 Dec 1]; Available from: https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-01840800\/full"},{"issue":"4","key":"361_CR53","first-page":"343","volume":"29","author":"A Gibofsky","year":"2023","unstructured":"Gibofsky A, Jacobson G, Franklin A, O\u2019Hara-Levi S, Peyrin-Biroulet L, McGrath M, et al. An online survey among US patients with immune-mediated conditions: attitudes about biosimilars. J Manag Care Spec Pharm. 2023 Apr;29(4):343\u201349.","journal-title":"J Manag Care Spec Pharm"},{"issue":"2","key":"361_CR54","doi-asserted-by":"publisher","first-page":"FSO369","DOI":"10.4155\/fsoa-2018-0101","volume":"5","author":"MR Ribeiro da Silva","year":"2019","unstructured":"Ribeiro da Silva MR, Ribeiro Dos Santos JB, Maciel Almeida A, Itria A, Maria Kakehasi A, Alvares Teodoro J, et al. Medication persistence for psoriatic arthritis in a Brazilian real-world setting. Future Science OA. 2019 Feb 1;5(2):FSO369.","journal-title":"Future Science OA"},{"issue":"5","key":"361_CR55","doi-asserted-by":"publisher","first-page":"S831","DOI":"10.1016\/S0016-5085(12)63225-9","volume":"142","author":"W Lu","year":"2012","unstructured":"Lu W, Gwee KA, Siah KTH, Lee RM, Ngan CCL.Gluten sensitization may be a possible pathogenic factor for IBS in a chinese population. Gastroenterology. 2012;142(5):S831.","journal-title":"Gastroenterology"}],"container-title":["Advances in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-024-00361-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42358-024-00361-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-024-00361-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T13:05:02Z","timestamp":1721135102000},"score":1,"resource":{"primary":{"URL":"https:\/\/advancesinrheumatology.biomedcentral.com\/articles\/10.1186\/s42358-024-00361-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,21]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["361"],"URL":"https:\/\/doi.org\/10.1186\/s42358-024-00361-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3030066\/v1","asserted-by":"object"}]},"ISSN":["2523-3106"],"issn-type":[{"value":"2523-3106","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,21]]},"assertion":[{"value":"6 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}